Galenica Grows In Switzerland With Dr. Wild OTC Portfolio
Executive Summary
Galenica has acquired an OTC portfolio from Switzerland's Dr. Wild, led by the market leading vitamin D supplements Vitamin D3 Wild Oil and VI-DE 3, which generated sales of CHF19m in 2020.
You may also be interested in...
Omicron And Acquisitions Push Up Galenica's Swiss OTC Sales By A Third
Galenica's Verfora substantially outpaced the 6.4% growth rate of the Swiss consumer health market in the first half, posting sales up by a third thanks to a combination of acquisitions and increased demand for cold & flu products due to the spread of the COVID-19 Omicron variant.
Acquisitions Help Drive Up Sales At Switzerland's Galenica In 2021
Galenica's Swiss consumer health business Verfora saw sales jump by a fifth in 2021 thanks to key acquisitions. Without the impact of these deals, Verfora's sales over the 12 months would have declined due to the negative impact of the pandemic on its business.
Euro Results Round-Up: Galenica, Recordati And Karo Pharma
The latest Q2 and first-half financial results from European consumer health players. Featuring Switzerland's Galenica, Italy's Recordati and Sweden's Karo Pharma.